3 March 2025
GENinCode
Plc
("GENinCode" or the "Company")
Result of General Meeting,
Issue of Equity and Total Voting Rights
GENinCode plc (AIM: GENI), the
genetics company focused on the prevention of cardiovascular
disease ("CVD") and the early detection of ovarian cancer,
announces that all resolutions put to Shareholders at the General
Meeting held earlier today in connection with the placing,
subscription and retail offer announced by the Company on 14
February 2025 were duly passed.
|
Resolution
|
For
|
Against
|
Withheld
|
Total votes
cast
|
|
|
|
Number of
votes
|
%
|
Number of
votes
|
%
|
Number of
votes
|
|
|
1
|
Ordinary resolution to authorise the
directors to allot shares
|
101,870,872
|
100%
|
-
|
0%
|
7
|
101,870,879
|
|
2
|
Special resolution to authorise the
directors to disapply pre-emption rights
|
101,866,990
|
100%
|
-
|
0%
|
3,889
|
101,870,879
|
(1) Any
proxy appointments, which gave discretion to the Chairman have been
included in the 'For' votes total.
(2) Votes
"For" and "Against" any resolution are expressed as a percentage of
votes validly cast for that resolution.
(3) A vote
"Withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against",
nor in the aggregate figure of total votes cast.
Subscription by the Nestor Oller entities
The Company has been notified by
Nestor Oller, a significant shareholder in the Company, of a change
in the legal entity subscribing for 9,459,460 shares, transferring
from Bobby Jean SICAV S.A. to Santi-1990 SL. Both entities are
undertakings controlled by Nestor Oller.
Issue of Equity and Total Voting Rights
Following shareholder approval at
the general meeting and conditional on admission, 88,040,541 new
ordinary shares have been allotted pursuant to the Placing,
1,809,508 new ordinary shares pursuant to the Retail Offer and
20,067,567 pursuant to the Subscription.
The Company has therefore allotted a
total of 109,917,616 new ordinary shares in connection with the
Fundraising.
Admission is expected to take place
at 8.00 a.m. on or around 4 March 2025.
Following Admission, the total
number of Ordinary Shares in the capital of the Company in issue
will be 286,882,042 with each Ordinary Share carrying the right to
one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the
Company will be 286,882,042.
The above figure may be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure, Guidance and Transparency
Rules.
Capitalised terms used in this
announcement have the meaning given to them in the announcement of
the Placing and Subscription dated 14 February 2025, unless
otherwise defined in this announcement.
Enquiries:
|
GENinCode Plc
Matthew Walls, CEO
Paul Foulger, CFO
Cavendish Capital Markets Limited (Nomad, Broker and Joint
Bookrunner)
|
www.genincode.com or
via Walbrook PR
Tel: +44
(0)20 7397 8900
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks (Life Sciences
Specialist Sales)
Ondraya Swanson (Corporate
Broking)
Dale Bellis / Michael Johnson
(Sales)
|
|
|
Oberon Capital (Joint Bookrunner)
Mike Seabrook / Aimee McCusker
(Corporate Broking)
Nick Lovering / Jessica Cave
(Corporate Finance)
|
Tel: +44 (0) 203 179 5300
corporatesales@oberoninvestments.com
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or
|
|
Anna Dunphy / Louis Ashe-Jepson /
Phillip Marriage
|
genincode@walbrookpr.com
|
